Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Valeo Pharma reports revenue jump to $13.5m for three months to end January
Canadian pharmaceutical company Valeo Pharma Inc (TSX: VPH) has reported a 3% increase in revenues for the three months to end January. The increase equates to $13.5 million and compares to $13.1 million from the previous corresponding quarter. The growth has been attributed to an uplift in sales generated from promotional activities for anaphylaxis preventer […]
March 26, 2024
Latest Stories
Biocure Technology to acquire Atriva Therapeutics in reverse takeover
Canadian biopharmaceutical firm Biocure Technology Inc (CSE: CURE) has secured a deal to acquire German company Atriva Therapeutics GmbH by way of a reverse takeover. Shareholders of Atriva will receive no less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. Under the terms of the […]
StageZero Life Sciences launches updated care oncology protocol for enhanced cancer treatment
Cancer research company StageZero Life Sciences (OTC: SZLSF) has launched an update to its proprietary care oncology (COC) protocol which uses advanced biomarker testing and an interactive digital health platform to make an enhanced connection between a patient’s metabolic health and cancer outcomes. Research has shown metabolically-targeted drugs have promise as an adjunctive therapy to […]
Alfa Instruments chooses Bausch + Lomb as exclusive global distributor for its surgical intraocular dyes
Leading global eye health company Bausch + Lomb (NYSE: BLCO) has entered into an agreement with Alfa Instruments where the Canadian company will distribute and commercialise Alfa Instruments’ line of surgical intraocular dyes in all countries except Italy. The exclusive distribution agreement struck between the two parties will see Bausch + Lomb’s surgical portfolio bolstered […]
BetterLife Pharma’s LSD-derivative treatment promotes structural neural plasticity in pre-clinical research
Pre-clinical research of BetterLife Pharma’s (CSE: BETR) lead drug a non-hallucinogenic psychedelic analogue has shown it promotes structural neural plasticity in an animal model along with anti-depressant effects. The second-generation drug BETR-001 is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD). During BetterLife’s pre-clinical trial, treating cortical rat neurons with BETR-001 increased the structural complexity […]
Clearmind Medicine reveals further positive pre-clinical results for cocaine addiction treatment
Clearmind Medicine (CSE: CMND) has achieved further positive pre-clinical results in its novel psychedelic molecule MEAI treatment for cocaine addiction. MEAI is the company’s flagship therapeutic and has low toxicity, along with a strong safety profile and no side effects. Through a recent study, results suggested MEAI can play a role in abolishing cocaine-induced conditioned […]
PharmaDrug completes key milestone to support cGMP production of lead candidate PD-001
PharmaDrug Inc (CSE: PHRX) has laid the groundwork to support multi-kilogram production of cepharanthine-2HCL for use in the final drug production of PD-001 to treat responsive cancers and COVID-19. PD-001 is the Toronto-based pharmaceutical company’s patented, oral, and bioavailable version of cepharanthine – a natural product and an approved drug used for more than 70 […]
Algernon Pharmaceuticals to present findings of Ifenprodil study for treatment of idiopathic pulmonary fibrosis
Clinical stage Canadian drug development company Algernon Pharmaceuticals (CSE: AGN) will present the results of a phase 2a study into NP-120 (Ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough at next year’s American Cough Conference. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. It […]
Optimi Health launches Blue Serenity, Canada’s first natural therapeutic psilocybin product
Optimi Health (CSE: OPTI) has launched Canada’s first natural therapeutic psilocybin product, Blue Serenity, in collaboration with psilocybin patient advocate, Thomas Hartle. Blue Serenity contains 25 milligrams of natural psilocybin in form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms, cultivated at Optimi Health’s labs in Princeton, British Columbia. Optimi chief science officer Justin Kirkland […]